MEDI-491 vaccine: Began Phase I trial of safety and immunogenicity in 20 healthy adult volunteers. Participants, in groups of four, will receive different doses

MedImmune Inc. (MEDI), Gaithersburg, Md. Product: MEDI-491 vaccine Indication: Infection by the B19 parvovirus of the cells that produce red blood cells Status: Began Phase I trial of safety and immun...